RxDoctor Payments DataLook up a doctor →

Venkatachalam Veerappan, MD

Neurology · Las Vegas, NVNPI 1154319432

Payments from drug & device makers

$21,851in general payments, 2019–2025

Across 560 payments — averaging $39.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$9K
  • EMD Serono, Inc.$2K
  • Biogen$1K
  • Acadia Pharmaceuticals Inc$965
  • SK Life Science, Inc.$933
  • AbbVie$901
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$1121%
  • Food & beverage$13,95398%
  • Education$2162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis101$8,659
EMD Serono, Inc.48$1,699
Biogen54$1,038
Acadia Pharmaceuticals Inc22$965
SK Life Science, Inc.19$933
AbbVie(2 entities)42$901
UCB, Inc.29$777
Neurocrine Biosciences, Inc.13$601
Genentech USA, Inc.13$511
Abbott6$476
Argenx US, Inc.13$436
Teva Pharmaceuticals USA, Inc.14$366
Sanofi12$356
AstraZeneca(2 entities)10$340
Amgen20$276
E.r. Squibb & Sons, L.L.C.2$274
Lundbeck LLC10$253
Catalyst Pharmaceuticals, Inc.3$199
ANI Pharmaceuticals, Inc.7$188
Lilly USA, LLC11$181
Pfizer9$170
Mallinckrodt Hospital Products Inc.5$143
Acorda Therapeutics, Inc8$128
Johnson & Johnson(2 entities)5$101
Takeda Pharmaceuticals U.S.A., Inc.4$100
Neurelis, Inc.5$98
Grifols USA, LLC4$98
Medtronic2$98
Otsuka America Pharmaceutical, Inc.4$96
Banner Life Sciences, LLC5$91
Springworks Therapeutics, Inc.3$83
Mallinckrodt Enterprises LLC3$78
Immedica Pharma US, Inc.2$76
Eisai Inc.3$74
Sunovion Pharmaceuticals Inc.3$65
Sanofi-aventis U.S. LLC3$64
Alnylam Pharmaceuticals Inc.2$63
TG Therapeutics, Inc.3$60
Biohaven Pharmaceutical Holding Company Ltd.3$48
Cala Health, Inc.2$48
Ipsen Biopharmaceuticals, Inc2$45
Adamas Pharmaceuticals, Inc.2$43
Vanda Pharmaceuticals Inc.2$41
Supernus Pharmaceuticals, Inc.3$39
CSL Behring2$38
Bristol Myers Squibb2$37
Octapharma USA, Inc.2$36
Tersera Therapeutics LLC1$34
Axsome Therapeutics, Inc.1$32
Biohaven Pharmaceuticals, Inc.2$27
Xeris Pharmaceuticals, Inc.1$25
Shire North American Group Inc1$24
Amneal Pharmaceuticals LLC1$24
Upsher-smith Laboratories LLC1$23
Boston Scientific1$21
Kyowa Kirin, Inc.1$21
Impel Pharmaceuticals Inc.1$19
Soleno Therapeutics, Inc.1$19
Strongbridge US Inc.1$19
Avanir Pharmaceuticals, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,851 in reported general payments places this provider in the 75th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada

Medicare billing

Part B allowed, 2024
$328,738
Medicare patients
732
Services billed
3,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5070$483,602
GammakedImmune Globul G/Gly/Iga Avg 4660$450,895
Gamunex-CImmune Globul G/Gly/Iga Avg 46120$448,771
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5051$447,924
OctagamImmun Globg(Igg)/Malt/Iga Ov5025$348,552
PanzygaImmun Glob G(Igg)-Ifas/Glycine42$174,792
Kesimpta PenOfatumumab17$158,073
XcopriCenobamate69$91,108
NuplazidPimavanserin Tartrate17$85,383
CopaxoneGlatiramer Acetate11$76,372
BriviactBrivaracetam38$60,722
Aimovig AutoinjectorErenumab-Aooe55$40,414
Emgality PenGalcanezumab-Gnlm34$27,697
Lacosamide158$24,452
KeppraLevetiracetam13$23,678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Panzyga, Eliquis$170$533,03583 claims
CSL BehringPrivigen$38$483,60270 claims
Grifols USA, LLCGamunex-C$98$448,771120 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$100$447,92451 claims
SK Life Science, Inc.Xcopri$933$91,10869 claims
Acadia Pharmaceuticals IncNuplazid$965$85,38317 claims
Teva Pharmaceuticals USA, Inc.Copaxone$366$76,37211 claims
UCB, Inc.Briviact$777$60,72238 claims
AbbVieUbrelvy, Qulipta$901$44,67428 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$24$4,78244 claims
Upsher-smith Laboratories LLCTopiramate$23$1,778147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 145 neurology providers in Nevada.

Other neurology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →